EGFR and neoplasm: A PFS of 20.6 months was reported for patients who received local ablative therapyat both primary tumor and oligometastatic sites,35 and another study revealed that 12 patients whoreceived EGFR-TKI and LCT had a PFS of 36 months.36 In contrast to previous standard continuous TKItreatment, we proposed a ctDNA-guided adaptive de-escalation treatment strategy thatdemonstrated a PFS of 18.4 (95% CI, 12.6-24.2) months.